SABCS2015

Radiotherapy to the Axilla Can Replace Axillary Lymph Node Dissection in Select Patients

Radiotherapy to the Axilla Can Replace Axillary Lymph Node Dissection in Select Patients

By

Recent trial data indicate that axillary lymph node dissection (ALND) can be safely omitted in select patients, according to a research presented at the 2015 San Antonio Breast Cancer Symposium.

A Review of Current Standards in the Optimal Management of the Axilla

A Review of Current Standards in the Optimal Management of the Axilla

By

The use of sentinel lymph node biopsy (SLNB) alone for care for axillary management in breast cancer patients with negative nodes is on the increase, according to study data presented at the 2015 San Antonio Breast Cancer Symposium.

Targeting Long noncoding RNAs in Breast Cancer May Prevent Tamoxifen Resistance

Targeting Long noncoding RNAs in Breast Cancer May Prevent Tamoxifen Resistance

By

New study findings presented at SABCS 2015 suggest that BRCAT431 promotes tamoxifen resistance, thereby increasing the clinical risk of recurrence and metastases in breast cancer.

Identifying Genetic Drivers of Breast Cancer Tumors and Metastasis

Identifying Genetic Drivers of Breast Cancer Tumors and Metastasis

By

A novel genetic driver analysis of matched breast cancer primary tumors and multiorgan metastases suggests that most genetic drivers in a single tumor are based on DNA copy number variants (CNV), are established early, and are maintained in metastases. These findings were presented at the 2015 San Antonio Breast Cancer Symposium.

Ten-year Overall Survival Is Higher After Breast-conserving Therapy Compared With Mastectomy in Early Stage Breast Cancer

Ten-year Overall Survival Is Higher After Breast-conserving Therapy Compared With Mastectomy in Early Stage Breast Cancer

By

Breast-conserving surgery with radiation therapy (BCT) demonstrated improved 10-year overall survival in patients with early stage breast cancer compared with mastectomy without radiation therapy, according to data presented at the 2015 San Antonio Breast Cancer Symposium.

EPclin Score Provides More Prognostic Information for Residual Distant Recurrence in ER+/HER2- Breast Cancer

EPclin Score Provides More Prognostic Information for Residual Distant Recurrence in ER+/HER2- Breast Cancer

By

EndoPredict (EP) provided superior information to the Oncotype DX recurrence score (RS) for distant recurrence (DR) in overall, N+, and N- patient populations, and also pinpointed a low-risk patient group who may not need chemotherapy.

Synthetic 2D Mammography Is Cost Effective and Reduces X-ray Exposure in Breast Cancer Screening Mammography

Synthetic 2D Mammography Is Cost Effective and Reduces X-ray Exposure in Breast Cancer Screening Mammography

By

Use of a synthetic 2D mammogram, instead of a standard 2d film, may offer breast cancer patients the benefits of 2D/3D screening combinations at a reduced radiation exposure level.

Adding Carboplatin to Neoadjuvant Therapy for Triple-negative Early Breast Cancer Improves Disease-free Survival

Adding Carboplatin to Neoadjuvant Therapy for Triple-negative Early Breast Cancer Improves Disease-free Survival

By

Carboplatin added to anthracycline/taxane-based neoadjuvant chemotherapy significantly improved pathological complete response rates in patients with triple-negative breast cancer in two large phase IIb studies: GeparSixto and CALGB 40603. Researchers reported on disease-free survival for GeparSixto after median 35 months of observation at the 2015 San Antonio Breast Cancer Symposium.

Premenopausal Patients With High-risk Luminal A Breast Cancer Get No Benefit From Adjuvant Chemotherapy

Premenopausal Patients With High-risk Luminal A Breast Cancer Get No Benefit From Adjuvant Chemotherapy

By

Premenopausal women with luminal A subtype breast cancer had comparable 10-year disease-free survival rates regardless of whether they received adjuvant chemotherapy, according to data presented at the 2015 San Antonio Breast Cancer Symposium.

Prophylactic Heart Failure Pharmacotherapy Is Safe and Effective in Patients With HER2-overexpressing Breast Cancer

Prophylactic Heart Failure Pharmacotherapy Is Safe and Effective in Patients With HER2-overexpressing Breast Cancer

By

Prophylactic use of standard HF pharmacotherapy appears to be effective for patients with HER2-overexpressing breast cancer.

Avelumab Demonstrated Clinical Activity in Subset of Patients With Metastatic Breast Cancer

Avelumab Demonstrated Clinical Activity in Subset of Patients With Metastatic Breast Cancer

By

Avelumab has an acceptable safety profile in patients with metastatic breast cancer and demonstrated signs of greater clinical activity in specific subsets of patients.

Nipple-sparing Mastectomy Offers Better Cosmetic and Psychological Outcomes for Patients With Breast Cancer

Nipple-sparing Mastectomy Offers Better Cosmetic and Psychological Outcomes for Patients With Breast Cancer

By

Nipple-sparing mastectomy and immediate breast reconstruction results in higher reported patient body image, when compared to skin-sparing partial mastectomy (SS-PM), and may lower risk of local recurrence.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs